Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension

INTRODUCTION: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort(®), Allergan, an AbbVie company) effectively reduces intraocular pressure (IOP) via complementary mechanisms of action of the agents, but long-term (> 12 weeks) safety evaluations of FCBT remain limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xinghuai, Yao, Ke, Liu, Qinghuai, Zhang, Hong, Xing, Xiaoli, Fang, Aiwu, Duan, Xuanchu, Yu, Minbin, Chen, Michelle Y., Yang, Jingyuan, Goodkin, Margot L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834455/
https://www.ncbi.nlm.nih.gov/pubmed/36370233
http://dx.doi.org/10.1007/s40123-022-00593-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834455/
https://www.ncbi.nlm.nih.gov/pubmed/36370233
http://dx.doi.org/10.1007/s40123-022-00593-w

Ejemplares similares